Dr. Arun Kanakkanthara, of Mayo Clinic, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With his project, “Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer,” Dr. Kanakkanthara is investigating ways to overcome tumor resistance to PARP inhibitors, a critical issue in ovarian cancer treatment. What initially sparked your interest in science? Science … Continued
Dr. Wei Zhou, of The Wistar Institute in Philadelphia, is a 2021 recipient of OCRA’s Ann & Sol Schreiber Mentored Investigator Award, mentored by Dr. Rugang Zhang. With his project, “Targeting the Mevalonate Pathway in ARID1A-Mutated Ovarian Cancer,” Dr. Zhou is investigating ARID1A mutations, in search of better therapeutic options for patients with ovarian clear … Continued
This time of year always has us reflecting on what we’ve accomplished, what we hope to achieve in the future, and how we — with the support of the entire ovarian cancer community — can lean in even harder to our commitment of being a voice for all those touched by the disease, and finding better treatments and a … Continued
Ovarian Cancer Research Alliance (OCRA) is proud to announce the establishment of a major new research partnership with Nicholas Firth and the Jean & Louis Dreyfus Foundation to be known as The Edmée Firth Fund for Research in Ovarian Cancer (EFFROC). Established with an initial gift of $1 million, OCRA will direct the fund toward critical areas of research, … Continued
An interdisciplinary group of researchers from around the country analyzed tumor samples from nearly 10,000 patients with 34 types of cancer to reveal unique genetic switches associated with each tumor type. The research, published in Science Advances and supported by multiple OCRA grants, turned up three potential drug targets for aggressive ovarian cancer, among other findings. Scientists … Continued
The application period has now closed. Apply today to join survivors, caregivers and activists across the country to affect change for those impacted by ovarian cancer. Advocate Leaders will learn how to educate federal and state policymakers about the disease, protect funding for lifesaving research, and fight for expanded access to treatment and care. No legislative or … Continued
Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” Dr. Ding is focusing on PARP inhibitors — some of the most effective drug therapies available for ovarian cancer, but that often come with a … Continued
Dr. Bojana Stefanovska, at University of Minnesota Twin Cities, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. Her project, “APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC,” explores DNA repair as a potential treatment avenue for clear cell ovarian carcinoma (CCOC). What initially sparked your interest in science? … Continued
Dear Friends, I hope this finds you all well, staying safe, and enjoying preparations for a lovely holiday. Whether you’re gathering with loved ones or holding them in your heart as you celebrate, I wish you warmth and joy. With the busy holiday season just around the corner, I’m grateful for this moment to reflect on … Continued
As we head into the Thanksgiving holiday, we have much to be thankful for … an embracing and strong survivor community, supporters who remain ever committed to the cause, and brilliant grantees who are making strides every day in the search for better treatments and a cure for ovarian cancer. Here’s a roundup of what’s … Continued
Clinical trials are fundamental to the discovery of new and better therapies in the fight against ovarian cancer. Yet enrollment and widespread availability remain a challenge. To address both financial barriers and inequity in participation, OCRA is urging Congress to pass the DIVERSE (Diversifying Investigations Via Equitable Research Studies for Everyone) Trials Act (H.R. 5030/S. … Continued
The following is a press release from University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, and Magee-Womens Research Institute PITTSBURGH, Nov. 12, 2021 – Immune checkpoint inhibitors are a type of cancer treatment that help the immune system’s T cells recognize and attack tumors. But these immunotherapy drugs aren’t effective against all cancers. In … Continued
Get email updates about research news, action alerts, and ways to join the fight.
